Table 2 Baseline clinical and laboratory data of the enrolled group.
Value | |
|---|---|
Age (years) | 41.6 ± 8.8 |
Sex (male/female) | 128/98 |
Weight (kg) | 128.7 ± 13.2 |
Body mass index (kg/m2) | 43.1 ± 4.6 |
Duration of diabetes mellitus | 6 (1–15) |
Hypertension | 114 (50.4%) |
Dyslipidemia | 98 (43.4%) |
Treatment of diabetes mellitus | |
Insulin therapy | 86 (38.1%) |
Number of oral hypoglycemic agents | 2 (1–4) |
Sulphonylurea | 158 (69.9%) |
Metformin | 190 (84.1%) |
Incretin mimics | 92 (40.7%) |
SGT2-inhibitor | 40 (17.7%) |
Pioglitazone | 16 (7.1%) |
Laboratory findings | |
C-peptide (ng/dL) | 3.8 ± 1.7 |
Fasting blood glucose (mg/dL) | 172.6 ± 63.5 |
Glycated hemoglobin (%) | 7.7 ± 1.2 |
Homeostatic Model Assessment of Insulin Resistance | 4.6 (1.3–12.4) |
